These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

16 related articles for article (PubMed ID: 31773635)

  • 1. Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis.
    Dhillon S
    Drugs; 2018 Apr; 78(5):607. PubMed ID: 29524073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer.
    Kang C; Dhillon S; Deeks ED
    Drugs; 2019 Oct; 79(15):1727. PubMed ID: 31535330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: Ivosidenib: First Global Approval.
    Dhillon S
    Drugs; 2019 Jan; 79(1):107. PubMed ID: 30610623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction to: Moxetumomab Pasudotox: First Global Approval.
    Dhillon S
    Drugs; 2019 Jan; 79(1):105. PubMed ID: 30612318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
    Dhillon S
    Clin Drug Investig; 2019 Apr; 39(4):419. PubMed ID: 30900188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction to: Dapagliflozin: A Review in Type 1 Diabetes.
    Paik J; Blair HA
    Drugs; 2019 Dec; 79(18):2011. PubMed ID: 31773634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus.
    Aylsworth A; Dean Z; VanNorman C; Nkemdirim Okere A
    Ann Pharmacother; 2014 Sep; 48(9):1202-1208. PubMed ID: 24951310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin--do we need it registered for type 2 diabetes?
    Doggrell SA; Tuli R
    Expert Opin Pharmacother; 2014 Aug; 15(11):1631-5. PubMed ID: 24998153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
    JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin for the treatment of chronic kidney disease.
    Kurata Y; Nangaku M
    Expert Rev Endocrinol Metab; 2022 Jul; 17(4):275-291. PubMed ID: 35822873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction to: Dapagliflozin: A Review in Type 2 Diabetes.
    Dhillon S
    Drugs; 2019 Dec; 79(18):2013. PubMed ID: 31773635
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.